Isotopia-global

Isotopia Molecular Imaging Ltd (Lutetium-177 production, c.a. and n.c.a.) — GMP radiometal production and certificate-of-analysis data for Lutetium-177, with an unusually explicit published process model: two competing production routes quantified side by side — direct/carrier-added (irradiation of enriched 176-Lu, ~5% material loss, product carries up to 0.07% long-lived 177m-Lu) versus indirect/no-carrier-added (irradiation of enriched 176-Yb followed by Yb separation, industry-typical ~25% material loss reduced to ~10% by the vendor's proprietary separation). Accompanied by per-batch relea…

Isotopia-global offers (Alternative, Supply Chain, Fundamental) — Low by record count, exceptionally high per-record density: roughly 10^3-10^4 GMP production batches since 2006 across four or more manufacturing sites, each carrying a multi-parameter certificate of analysis measured at two timepoints (inferred from a near-20-year production history on a weekly-to-campaign cadence; supply is measured in curies per shipment — licence correspondence references Lu-177 quantities up to 29 Ci per consignment — not in bulk records).

Radiometal process-yield benchmarking across production routes and manufacturers — the route-transfer history means the same process has been executed and measured at multiple independent GMP sites, which is a rare reproducible-process dataset; isotope supply-reliability and capacity-utilisation models for the expanding radioligand-therapy market (production cadence, 52-week commitments and multi-site redundancy are the constraints that actually gate therapy rollouts); radionuclidic purity outcome prediction from route and process parameters; radiopharmaceutical waste and long-lived-impurity burden modelling (the absence of 177m-Lu is explicitly a waste-management advantage, so its presence is an economically meaningful label); decay and stability modelling from paired-timepoint specific-activity measurements; and alternative-data scarcity signals on Lu-177 availability for investors pricing publicly-listed radioligand developers.

The data is with 20 years of history.